Financial Performance - Revenue for Q3 2022 reached ¥176,274,055.13, an increase of 68.83% compared to the same period last year[6] - Net profit attributable to shareholders was ¥55,428,312.55, a significant increase of 341.96% year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥50,310,597.80, up 320.88% from the previous year[6] - Basic earnings per share for Q3 2022 was ¥0.44, representing a 238.46% increase compared to the same period last year[6] - Operating revenue for the period reached ¥422,920,517.10, up from ¥388,432,669.66, reflecting a growth of about 8.9%[35] - Net profit for the period was ¥109,484,923.35, compared to ¥65,885,589.37 in the previous period, indicating a significant increase of approximately 66%[38] - The total comprehensive income attributable to the parent company for Q3 2022 was ¥109,152,877.34, compared to ¥66,059,761.13 in Q3 2021, representing a significant increase[40] - Basic and diluted earnings per share for Q3 2022 were both ¥0.87, up from ¥0.70 in the same period last year, indicating a growth of approximately 24.3%[40] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥1,500,609,700.03, an increase from ¥1,393,711,531.79 at the end of the previous year[8] - Total liabilities amounted to ¥307,204,992.92, up from ¥296,351,894.49, which is an increase of approximately 3%[34] - The company's cash and cash equivalents increased, contributing to improved liquidity[31] - Inventory levels rose to ¥242,486,399.22 from ¥167,083,176.30, indicating a growth of approximately 45%[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,891[16] - The largest shareholder, Yang Xining, holds 27.34% of the shares, totaling 34,446,500 shares[16] - SHENGLIN HOLDING CO. LTD. is the second-largest shareholder with a 15.79% stake, amounting to 19,890,000 shares[16] - The third-largest shareholder, Beijing Xinhua Lian Industrial Investment Co., Ltd., holds 10.71% with 13,500,000 shares[16] - The total number of restricted shares held by Yang Xining remains unchanged at 34,446,500 shares, with a release date set for October 26, 2024[20] - The total number of restricted shares at the end of the reporting period is 96,559,280 shares, with 866,200 shares added during the period[24] - The company has not disclosed any related party relationships among the top ten unrestricted shareholders[19] - There are no reported changes in the number of restricted shares for other major shareholders during the period[20] Cash Flow - Cash flow from operating activities showed a net inflow of ¥64,584,440.06, a decrease of 13.57% year-on-year[6] - Cash inflow from operating activities for Q3 2022 totaled ¥364,326,777.04, compared to ¥284,408,561.51 in Q3 2021, reflecting an increase of about 28.1%[44] - The net cash flow from operating activities for Q3 2022 was ¥64,584,440.06, down from ¥74,723,337.42 in Q3 2021, showing a decrease of approximately 13.3%[44] - Cash inflow from investment activities for Q3 2022 was ¥514,151,481.94, significantly higher than ¥10,000,000.00 in Q3 2021[46] - The net cash flow from investment activities for Q3 2022 was -¥71,628,179.98, compared to -¥50,512,308.65 in Q3 2021, indicating a larger outflow year-over-year[46] - Cash inflow from financing activities for Q3 2022 was ¥80,000,000.00, down from ¥131,400,000.00 in Q3 2021, a decrease of approximately 39.1%[46] - The net cash flow from financing activities for Q3 2022 was -¥1,746,173.48, compared to -¥16,090,049.38 in Q3 2021, showing an improvement in cash flow management[46] - The ending cash and cash equivalents balance for Q3 2022 was ¥226,440,815.64, compared to ¥75,066,298.77 at the end of Q3 2021, indicating a substantial increase[46] - The company reported a total of ¥310,048,077.00 in cash received from sales and services in Q3 2022, compared to ¥253,820,495.93 in Q3 2021, marking an increase of approximately 22.1%[44] Research and Development - Research and development expenses increased by 36.90% to ¥19,034,128.86 for the first nine months of 2022[13] - Research and development expenses rose to ¥19,034,128.86 from ¥13,903,474.34, marking an increase of about 36.5%[38] Future Outlook - The company plans to continue expanding its market presence and investing in new product development[38]
拓新药业(301089) - 2022 Q3 - 季度财报